To determine if pharmacological inhibition of USP25 is effective in reducing the expression levels of KRAS protein and in tempering KRAS signaling, we treated HT29 colon cancer cells (which do not harbor mutations in KRAS) with different concentrations of CT1113 (Fig. 4A). This evidence concerns the gene KRAS and malignant colon neoplasm.